We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Clinicopathological characteristics and eligibility for adjuvant olaparib of germline BRCA1/2 mutation carriers with HER2-negative early breast cancer.
- Authors
Morganti, Stefania; Jin, Qingchun; Vincuilla, Julie; Buehler, Ryan; Ryan, Sean; Stokes, Samantha; Parker, Tonia; Mittendorf, Elizabeth A.; King, Tari A.; Weiss, Anna; Partridge, Ann H.; Bychkovsky, Brittany L.; Curigliano, Giuseppe; Tayob, Nabihah; Lin, Nancy U.; Garber, Judy E.; Tolaney, Sara M.; Lynce, Filipa
- Abstract
Following the survival benefit demonstrated in the OlympiA trial, one year of adjuvant olaparib is now recommended for all patients with germline BRCA1/2 pathogenic/likely pathogenic variants (PV) and high-risk, HER2-negative early breast cancer after chemotherapy. However, optimal identification of high-risk patients who may derive benefit from this genomically-directed therapy is debated. In this study, we sought to characterize the real-world proportion of gBRCA1/2 PV carriers eligible for adjuvant olaparib according to the OlympiA criteria, and to compare clinicopathologic characteristics and outcomes between eligible and ineligible patients.
- Subjects
OLYMPIA (Wash.); BREAST cancer; OLAPARIB; GERM cells; CLINICAL pathology; CANCER chemotherapy; METASTATIC breast cancer
- Publication
NPJ Breast Cancer, 2024, Vol 10, Issue 1, p1
- ISSN
2374-4677
- Publication type
Article
- DOI
10.1038/s41523-024-00632-8